

Special Issue

Metastatic Brain Tumors Research

Message from the Guest Editor

Dear Colleague, Over recent years, the incidence rates of brain metastatic disease have risen to levels comparable to those of primary brain tumors. Nevertheless, clinical efforts in trials on brain metastatic disease remain relatively understudied, just as initiating basic research projects on this topic. In addition to significant variations between different tumor lineages and primary sites giving rise to brain metastases, many still unknown factors seem to influence the likelihood for developing this fatal complication. The development of therapeutic—or preventive—strategies is in urgent need of basic scientific data. This Issue presents a cross section of the various fronts of current research activity in this highly varied and complicated field.

Guest Editor

Prof. Dr. Johan Max Kros

Department of Pathology, Erasmus Medical Center, Wytemaweg 80,
3000 DR Rotterdam, The Netherlands

Deadline for manuscript submissions

closed (30 September 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/57638

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)